A Study of Dose Escalation of ES502 in Patients With Advanced Pancreatic Cancer

Abroad (travel likely)RecruitingEARLY_PHASE1

Conditions

Pancreatic Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Chenlei Wen) · wcl12161@rjh.com.cn · +86-13761638756
Contact: Principal Investigator (Baiyong Shen)

Study leads

Baiyong Shen
Study Director
Ruijin Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer

Pancreatic Cancer · Adjuvant Therapy

Abroad (travel likely)RecruitingPHASE1

Chengdu, China

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

Pancreatic Cancer · Renal Cell Cancer · Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

EXoPERT EMERALD Clinical Study

Breast Cancer · Colon Cancer · Pancreatic Cancer

Abroad (travel likely)Recruiting

Long Beach, United States · Los Angeles, United States

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Phase 2 Study · BMS-986504 · MTAP-deleted Pancreatic Cancer

Abroad (travel likely)RecruitingPHASE2

Houston, United States